PEPTIDE TALK

Vicky Eldridge asks how we separate the science from the social media hype when it comes to copper peptides

C opper peptides are having a moment. Once a relatively niche skincare ingredient, they have become one of the latest buzzword actives for consumers looking to improve skin quality, support collagen production and tap into the promise of regenerative skincare.

But the conversation is moving beyond topical use. Injectable copper peptides, or GHK-Cu, are increasingly being discussed within biohacking, longevity and wellness circles, where claims extend from better skin to hair growth, wound healing, recovery, and systemic anti-ageing benefits.

There is just one important problem: putting a copper peptide on the skin and injecting it into the body are two very different propositions.

While topical copper peptides have decades of cosmetic use behind them and a growing, albeit still developing, body of research, injectable GHK-Cu does not have the same established clinical evidence base.

So how did we get from copper peptide skincare to people injecting the molecule – and where has enthusiasm run ahead of evidence?

For Dr Patrick Treacy, it reflects a wider phenomenon facing aesthetic medicine, where scientific research can rapidly move from journals to podcasts, TikTok, online forums and consumer treatments before clinical research has established how, or even whether, it should be used.

He says: “A generation now reads a mechanism paper on a Saturday and injects on a Sunday. The leap from topical to subcutaneous was not made by clinical evidence. It was made by supply chains and podcasts.”

WHAT DOES THE SCIENCE ACTUALLY SAY?

GHK, or glycyl-L-histidyl-L-lysine, is a naturally occurring tripeptide with a strong affinity for copper. First identified in human plasma in the 1970s, it has attracted scientific interest for its potential involvement in wound healing, tissue remodelling and regenerative processes.

Dr Treacy explains: “The preclinical data are genuinely interesting and I would not dismiss them. GHK-Cu upregulates collagen I and III, elastin, decorin and glycosaminoglycans, modulates the MMP/TIMP balance, supports angiogenesis, and in gene-expression work appears to shift cells toward a more youthful transcriptional profile. That is real biology.”

But interesting biology and proven treatment are not the same thing.

“There are no adequately powered human trials of injected GHK-Cu for skin quality, hair growth, recovery or systemic anti-ageing. Absence of evidence is not evidence of absence, but it is also not a licence,” Dr Treacy adds.

Dr Steve Harris, an aesthetic doctor known for advocating a more evidence-based approach to aesthetic medicine, shares this concern.

“I am very concerned, particularly because social media can turn a biologically interesting substance into an apparent treatment almost overnight. Repetition creates familiarity and familiarity can easily be mistaken for evidence.

Injectable peptides are another example of commercial availability being mistaken for clinical validation.

“With injectable GHK-Cu, we do not have robust clinical evidence establishing what it treats, whether it produces meaningful benefits in humans, the appropriate dose or frequency, or its short- and long-term systemic safety. Injection also introduces additional issues around sterility, purity, degradation products, immune reactions and consistency of manufacture.

“A plausible mechanism tells us that something might work. Clinical evidence tells us if it actually benefits patients, at what dose, for which indication and at what cost in terms of risk.”

A DECLINE IS NOT A DEFICIENCY

One argument used to support GHK-Cu supplementation is that circulating levels appear to decline with age – something that can easily be reframed through the language of longevity medicine as a deficiency requiring “optimisation”.

Dr Treacy urges caution. “The argument used to justify injection is that plasma GHK falls with age. This is where I would apply what I call biological honesty. A decline is not a deficiency. Ageing is not a deficiency disease. The fall in circulating GHK is far more likely to be downstream of chronic inflammation and altered protein turnover than an upstream cause we can correct by topping up a reservoir.”

COMMERCIAL AVAILABILITY VERSUS CLINICAL VALIDATION

Patients may understandably assume that if a product can be purchased, openly discussed and even administered, it must have undergone some level of clinical validation.

” Injectable peptides are another example of commercial availability being mistaken for clinical validation,” says Dr Harris. “Terms such as ‘regenerative’, ‘biohacking’ and ‘longevity’ can make a treatment sound scientifically established when the underlying evidence consists of laboratory studies, animal data, mechanistic hypotheses and testimonials.”

But this does not mean dismissing GHK-Cu as scientifically irrelevant.

“GHK-Cu is biologically interesting and I think deserves further research,” Dr Harris adds. “That’s very different from saying that systemic injection is currently an established anti-ageing, hair-growth or regenerative treatment.”

For practitioners, the threshold for adopting a new injectable therapy should therefore extend far beyond a plausible mechanism or growing consumer demand.

Dr Harris believes practitioners should look for well-designed human trials, clearly defined indications and clinically meaningful outcomes, alongside pharmacological and toxicological data, standardised dosing, reliable manufacturing and regulatory oversight.

“If those elements are absent, the treatment should be described honestly as experimental rather than presented as established medicine.”

WHAT ARE THE RISKS?

Without robust clinical trials and systematic surveillance, it is difficult to establish the true risk profile of injectable GHK-Cu.

“The absence of reported complications should not be interpreted as evidence of safety,” warns Dr Harris. “Without systematic trials, surveillance and transparent reporting, we may simply not know what complications are occurring.”

Dr Treacy also challenges the assumption that because GHK-Cu occurs naturally within the body, introducing more must be inherently safe.

“Copper is not an inert carrier. It is a redox-active transition metal. Free copper drives Fenton chemistry and oxidative injury, and cuproptosis is now a recognised cell death pathway. Systemic copper loading has hepatic and neurological consequences and disturbs zinc homeostasis. GHK-Cu also shows a biphasic dose response – the concentrations that stimulate at low levels can be cytotoxic at high ones – and nobody self-dosing from an unlabelled vial is anywhere near that curve deliberately.”

He also raises questions around angiogenesis and product sourcing.

“The angiogenesis point deserves more attention than it gets. Copper is a well-established angiogenic cofactor, which is precisely why copper chelation has been investigated as an anti-angiogenic strategy in oncology. Promoting systemic angiogenesis in a patient with an undiagnosed malignancy is not a theoretical concern. Add to that unregulated research-grade material of unknown sterility, endotoxin load and actual copper content, reconstituted on a kitchen counter, and the risk profile is no longer about efficacy at all.”

These concerns do not mean everyone injecting GHK-Cu will experience harm. But they do demonstrate how much remains unknown, particularly when products may be obtained outside conventional pharmaceutical supply chains and used according to protocols shared online.

WHAT ABOUT TOPICAL COPPER PEPTIDES?

It is important not to conflate concerns around injectable GHK-Cu with topical copper peptides, which have a considerably longer history of cosmetic use.

Victoria Hiscock, skin science educator, says research around topical copper peptides has demonstrated interesting activity relating to fibroblasts, collagen synthesis, extracellular matrix remodelling and antioxidant activity, alongside a long history of use in post-procedural skincare.

However, she cautions against extrapolating promising cellular science into exaggerated claims about visible results.

“While the science behind what copper peptides can do on cellular level is very exciting, translating that into measurable and visible results with an end formula is a very different quest. End-formulation human trials don’t yet support some of the claims coming through about what copper peptides can do on real skin – so we can’t yet say it’s the best thing since sliced retinoids.”

For now, she sees copper peptides as complementary to, rather than replacements for, established skincare actives.

“At this moment in time, copper peptides don’t yet have main character energy in skincare. The industry isn’t offering a plethora of copper peptide-only formulas; instead, it’s smartly combined with other actives into multi-tasking, hybrid formulas. It sits symbiotically with established actives and contributes to a wider patient skincare journey across pre-and-post procedural care. But the evidence is exciting, so watch this space.”

The key distinction is that evidence and decades of cosmetic experience relating to topical use cannot simply be extrapolated to justify systemic injection.

WHAT SHOULD PRACTITIONERS DO WHEN PATIENTS ASK?

Patients increasingly arrive at consultations having researched treatments through TikTok, podcasts, Reddit and longevity influencers. Some may already be injecting peptides without considering them relevant to disclose before aesthetic treatment. Dr Treacy believes the first step is simple: ask. “Peptide use is rarely volunteered and rarely singular – GHK-Cu is usually stacked with BPC-157, TB-500 or others. Document it before you treat.”

He also advises practitioners to be alert to potential red flags, including hepatic disease, disorders of copper handling and active or recent malignancy.

Equally important is how practitioners respond to patients who are interested in these treatments.

“I would not dismiss the patient,” says Dr Harris. “Their interest is understandable because these treatments are often presented very persuasively and wrapped in scientific language.

“I would first ask what benefit they are hoping to achieve, then explain what is known, what is only theoretically plausible and what remains unknown. It’s important to distinguish topical cosmetic use from systemic injection, because changing the route of administration changes the biological exposure and the risk.” He adds: “I would explain that ‘naturally occurring’ does not automatically mean safe when a substance is manufactured, concentrated and injected. I would also discuss the absence of validated dosing, reliable long-term safety data and regulatory authorisation.”

Our role is not to police enthusiasm. It is to be the safeguard between an interesting mechanism and an unproven intervention.

Dr Treacy agrees that dismissing patients risks driving them towards less reliable sources of information.

“Do not be dismissive. The patient asking about copper peptides is not foolish. They have read something real and drawn an unsupported conclusion from it. If we meet that with contempt, they will simply go and get worse advice from someone selling it.”

“Our role is not to police enthusiasm. It is to be the safeguard between an interesting mechanism and an unproven intervention and to say plainly that topical GHK-Cu has thirty years behind it, while injectable GHK-Cu has a forum thread.”

PROMISING SCIENCE SHOULD NOT BECOME PREMATURE MEDICINE

Copper peptides are a fascinating area of research, and their renewed popularity reflects the growing convergence of regenerative aesthetics, skincare and longevity medicine.

But the fact that a molecule occurs naturally in the body or demonstrates interesting biological activity does not automatically establish that injecting it is safe, effective or appropriate.

Future research may change what we know. Promising science should be investigated, but innovation and evidence need to happen in the right order.

As Dr Harris says: “Innovation is important, but it should begin with a question and then generate evidence. It should not begin with widespread treatment followed by an attempt to justify it retrospectively.”